These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16716362)

  • 1. ENOS is not activated by nebivolol in human failing myocardium.
    Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
    Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.
    Reidenbach C; Schwinger RH; Steinritz D; Kehe K; Thiermann H; Klotz T; Sommer F; Bloch W; Brixius K
    Life Sci; 2007 Jun; 80(26):2421-7. PubMed ID: 17512554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium.
    Napp A; Brixius K; Pott C; Ziskoven C; Boelck B; Mehlhorn U; Schwinger RH; Bloch W
    J Card Fail; 2009 Feb; 15(1):57-67. PubMed ID: 19181295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium.
    Brixius K; Bloch W; Ziskoven C; Bölck B; Napp A; Pott C; Steinritz D; Jiminez M; Addicks K; Giacobino JP; Schwinger RH
    Can J Physiol Pharmacol; 2006 Oct; 84(10):1051-60. PubMed ID: 17328145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
    Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
    Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium.
    Brixius K; Bloch W; Pott C; Napp A; Krahwinkel A; Ziskoven C; Koriller M; Mehlhorn U; Hescheler J; Fleischmann B; Schwinger RH
    Br J Pharmacol; 2004 Dec; 143(8):1014-22. PubMed ID: 15466444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
    Wolf SC; Buck-Müller N; Görner S; Risler T; Brehm BR
    Med Klin (Munich); 2003 Jan; 98(1):1-6. PubMed ID: 12540987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
    Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
    J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
    Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
    Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
    Toblli JE; Cao G; Casas G; Mazza ON
    Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.